Skip to main content

Table 1 Characteristics of patients diagnosed with CTD and IM

From: Invasive mycoses in patients with connective tissue disease from Southern China: clinical features and associated factors

Characteristics

SLE (n = 19)

AAV (n = 7)

PM/DM (n = 3)

RA (n = 2)

SSc (n = 1)

Demographic characteristics

 Sex, male to female

5:14

1:6

1:2

0:2

0:1

 Age, years, mean ± SD

35.6 ± 15.3

53.1 ± 13.0

57.0 ± 4.4

46.5 ± 9.2

46.0

 Duration of CTD, months, median (IQR)

4(1.0,21.0)

3(0.3,84.0)

120(61.5,180.0)

204(186.0,222.0)

108.0

 Diabetes mellitus, n (%)

3(15.8)

1(14.3)

0(0)

0(0)

0(0)

 Nephritis, n (%)

15(78.9)

4(57.1)

0(0)

0(0)

0(0)

 Interstitial pneumonia, n (%)

1(5.3)

3(42.9)

1(33.3)

0(0)

1(100.0)

Laboratory data

 WBC count (× 109), mean ± SD

9.5 ± 6.7

10.7 ± 6.0

12.9 ± 5.6

8.8 ± 1.2

6.6

 Lymphocyte count (× 109), mean ± SD

0.9 ± 1.0

0.8 ± 0.7

1.1 ± 0.4

1.5 ± 1.0

0.7

 Hemoglobin (g/l), mean ± SD

96.1 ± 26.2

87.3 ± 27.5

116.7 ± 2.5

114.5 ± 3.5

109.0

 Serum albumin (g/l), mean ± SD

28.1 ± 7.4

32.8 ± 3.5

27.0 ± 11.3

35.5 ± 4.9

32.0

 Elevated serum creatinine, n (%)

6(31.6)

6(85.7)

0(0)

0(0)

0(0)

 IgM (g/l), median (IQR)

0.7(0.3,0.9)

0.5(0.4,0.8)

1.2(1.1,1.4)

0.7(0,0.5)

0.3

 IgG (g/l), median (IQR)

15.4(7.4,17.4)

13.4(12.6,20.4)

15.2(14.4,16.0)

14.8(0,11.8)

14.1

 ESR (mm/h),median (IQR)

45.0(39,58.5)

63.0(60,66.0)

87.5(81.8,93.3)

49.5(43.3,55.8)

30.0

 CRP (mg/l), median (IQR)

11.0(6.2,33.4)

12.3(6.3,20.1)

102.0(52.7,139.0)

65.6(34.4,96.8)

0.6

Treatment prior to IM

 Median-to-high dose of GC, n (%)

6(31.6)

3(42.9)

2(66.7)

0(0)

0(0)

 CYC, n (%)

4(21.1)

4(57.1)

1(33.3)

0(0)

0(0)

 MMF, n (%)

3(15.8)

0(0)

0(0)

0(0)

0(0)

 CsA, n (%)

2(10.5)

0(0)

0(0)

1(50.0)

0(0)

 MTX, n (%)

1(5.3)

0(0)

0(0)

1(50.0)

0(0)

  1. AAV ANCA-associated vasculitis, CRP C-reactive protein, CsA cyclosporine A, CTD connective tissue disease, CYC cyclophosphamide, ESR erythrocyte sedimentation rate, GC glucocorticoid, IM invasive mycoses, IQR interquartile range, MMF mycophenolate mofetil, MTX methotrexate, PM/DM polymyositis/dermatomyositis, RA rheumatoid arthritis, SD standard deviation, SLE systemic lupus erythematosus, SSc systemic sclerosis, WBC white blood cell